IL-17-Producing Cells in Tumor Immunity: Friends or Foes?

Kuen, Da-Sol; Kim, Il‐Kyu; Chung, Yeonseok

doi:10.4110/in.2020.20.e6

Cited by 99 publications

(78 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-23 is a primary trigger of Th17 lymphocytes that are known to be highly immunosuppressive [ 18 , 68 ]. Th17 cells secrete pro-inflammatory cytokines such as IL-17A, which impair immune surveillance and promote tumor growth [ 124 , 125 , 126 ]. A few mechanisms revealing the Th17-dependent suppression of anti-tumor immunity have been proposed [ 127 , 128 ].…”

Section: Myc–a Key Player In the Tumor Microenvironment (Tme)mentioning

confidence: 99%

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

Meškytė

Keskas

Ciribilli

2020

IJMS

View full text Add to dashboard Cite

The Myc family of oncogenes is deregulated in many types of cancer, and their over-expression is often correlated with poor prognosis. The Myc family members are transcription factors that can coordinate the expression of thousands of genes. Among them, c-Myc (MYC) is the gene most strongly associated with cancer, and it is the focus of this review. It regulates the expression of genes involved in cell proliferation, growth, differentiation, self-renewal, survival, metabolism, protein synthesis, and apoptosis. More recently, novel studies have shown that MYC plays a role not only in tumor initiation and growth but also has a broader spectrum of functions in tumor progression. MYC contributes to angiogenesis, immune evasion, invasion, and migration, which all lead to distant metastasis. Moreover, MYC is able to promote tumor growth and aggressiveness by recruiting stromal and tumor-infiltrating cells. In this review, we will dissect all of these novel functions and their involvement in the crosstalk between tumor and host, which have demonstrated that MYC is undoubtedly the master regulator of the tumor microenvironment. In sum, a better understanding of MYC’s role in the tumor microenvironment and metastasis development is crucial in proposing novel and effective cancer treatment strategies.

show abstract

Section: Myc–a Key Player In the Tumor Microenvironment (Tme)mentioning

confidence: 99%

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

Meškytė

Keskas

Ciribilli

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The expression of IL-17a mRNA increases with the increase of tumor invasion and pathological stage. However, IL-17a has different promotion effects on tumor angiogenesis [54]. For example, in non-small cell carcinoma, IL-17a increases vascular proliferation by promoting the angiogenic chemokines C-X-C motif chemokine ligand (CXCL)1, 5, and 8.…”

Section: Intestinal Microbiota Regulates Immune Responses In the Bodymentioning

confidence: 99%

“…For example, in non-small cell carcinoma, IL-17a increases vascular proliferation by promoting the angiogenic chemokines C-X-C motif chemokine ligand (CXCL)1, 5, and 8. In human melanoma blood vessels, IL-17a upregulates the expression of vascular genes through an IL-6-dependent mechanism [54]. However, IL-17f has an inhibitory effect on tumor angiogenesis [55].…”

Section: Intestinal Microbiota Regulates Immune Responses In the Bodymentioning

confidence: 99%

Intestinal microbiota: a new force in cancer immunotherapy

Dai

Zhang

et al. 2020

Cell Commun Signal

View full text Add to dashboard Cite

Cancer displays high levels of heterogeneity and mutation potential, and curing cancer remains a challenge that clinicians and researchers are eager to overcome. In recent years, the emergence of cancer immunotherapy has brought hope to many patients with cancer. Cancer immunotherapy reactivates the immune function of immune cells by blocking immune checkpoints, thereby restoring the anti-tumor activity of immune cells. However, immune-related adverse events are a common complication of checkpoint blockade, which might be caused by the physiological role of checkpoint pathways in regulating adaptive immunity and preventing autoimmunity. In this context, the intestinal microbiota has shown great potential in the immunotherapy of cancer. The intestinal microbiota not only regulates the immune function of the body, but also optimizes the therapeutic effect of immune checkpoint inhibitors, thus reducing the occurrence of complications. Therefore, manipulating the intestinal microbiota is expected to enhance the effectiveness of immune checkpoint inhibitors and reduce adverse reactions, which will lead to new breakthroughs in immunotherapy and cancer management.

show abstract

“…For instance, in non-small cell lung cancer, IL-17f increases the invasion by promoting angiogenetic chemokines. On the contrary, in CRC, IL-17f suspends angiogenesis through the reduction of vascular endothelial growth factor [ 55 , 56 ].…”

Section: Gut Microbiota and Immunotherapymentioning

confidence: 99%

Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer

Koulouridi

Messaritakis

Gouvas

et al. 2020

Cancers

View full text Add to dashboard Cite

Over the last few years, immunotherapy has been considered as a key player in the treatment of solid tumors. Immune checkpoint inhibitors (ICIs) have become the breakthrough treatment, with prolonged responses and improved survival results. ICIs use the immune system to defeat cancer by breaking the axes that allow tumors to escape immune surveillance. Innate and adaptive immunity are involved in mechanisms against tumor growth. The gut microbiome and its role in such mechanisms is a relatively new study field. The presence of a high microbial variation in the gut seems to be remarkably important for the efficacy of immunotherapy, interfering with innate immunity. Metabolic and immunity pathways are related with specific gut microbiota composition. Various studies have explored the composition of gut microbiota in correlation with the effectiveness of immunotherapy. Colorectal cancer (CRC) patients have gained little benefit from immunotherapy until now. Only mismatch repair-deficient/microsatellite-unstable tumors seem to respond positively to immunotherapy. However, gut microbiota could be the key to expanding the use of immunotherapy to a greater range of CRC patients.

show abstract

IL-17-Producing Cells in Tumor Immunity: Friends or Foes?

Cited by 99 publications

References 145 publications

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

Intestinal microbiota: a new force in cancer immunotherapy

Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer

Contact Info

Product

Resources

About